A comprehensive review on synthetic strategy and MOA of marketed drugs having therapeutically potential chemical entity pyrazole

被引:0
作者
Singh, Sucheta [1 ]
Singh, Kuldeep [2 ]
Tahlan, Sumit [3 ]
机构
[1] Maharshi Dayanand Univ, Dept Pharmaceut Sci, Rohtak 124001, India
[2] Kurukshetra Univ, Dept Chem, Kurukshetra 136119, India
[3] Natl Inst Malaria Res, ICMR, New Delhi 110077, India
关键词
Pyrazole derivatives; Marketed drugs; Synthetic route; MOA; Therapeutic uses; EFFICIENT SYNTHESIS; PHARMACOLOGICAL-PROPERTIES; ANTIOXIDANT ACTIVITY; RIMONABANT; DERIVATIVES; SELECTIVITY; SILDENAFIL; INHIBITORS; ANTIBACTERIAL; HETEROCYCLES;
D O I
10.1007/s13738-024-03095-7
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nitrogen-containing heterocycles have been desirable targets for synthesis for many years because of their structural diversity and biological significance. Five-membered heterocyclic rings, or pyrazole, are a flexible starting point for the design of effective bioactive compounds and are widely used in medicinal chemistry, drug discovery, agrochemistry, coordination chemistry, and organometallic chemistry. Pyrazole derivatives have played an important role in heterocyclic chemistry and have been extensively studied owing to their ease of access, diversified chemical reactivity, and broad biological properties, including antibacterial, anti-inflammatory, anticancer, analgesic, anticonvulsant, anthelmintic, antioxidant, and herbicidal properties. Pyrazole nuclei are synthesized via a variety of methods, including the multicomponent approach, dipolar cycloaddition, cyclocondensation of hydrazine with a carbonyl system, heterocyclic system, and multicomponent approach. The current review is an attempt to understand the chemistry and medicinal importance of the pyrazole-containing marketed drugs reported to date, which will undoubtedly assist the scientific community in making further advances in the isolation and synthesis of pyrazole-based novel bioactive compounds.
引用
收藏
页码:2531 / 2564
页数:34
相关论文
共 182 条
[21]  
Brown EG., 1998, BIOCH N HETEROCYCLES, P242
[22]  
Brune K, 2001, CLIN EXP RHEUMATOL, V19, pS51
[23]  
BUCHANAN MR, 1983, THROMB RES, P89
[24]   ALLOPURINOL PRODRUGS .1. SYNTHESIS, STABILITY AND PHYSICOCHEMICAL PROPERTIES OF VARIOUS N-1-ACYL ALLOPURINOL DERIVATIVES [J].
BUNDGAARD, H ;
FALCH, E .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1985, 23 (02) :223-237
[25]   Synthesis of 4-Aminopyrazol-5-ols as Edaravone Analogs and Their Antioxidant Activity [J].
Burgart, Yanina, V ;
Makhaeva, Galina F. ;
Krasnykh, Olga P. ;
Borisevich, Sophia S. ;
Agafonova, Natalia A. ;
Kovaleva, Nadezhda, V ;
Boltneva, Natalia P. ;
Rudakova, Elena, V ;
Shchegolkov, Evgeny, V ;
Triandafilova, Galina A. ;
Gazizov, Denis A. ;
Serebryakova, Olga G. ;
Ulitko, Maria, V ;
Khursan, Sergey L. ;
Saloutin, Victor, I ;
Richardson, Rudy J. .
MOLECULES, 2022, 27 (22)
[26]   Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review [J].
Byon, Wonkyung ;
Garonzik, Samira ;
Boyd, Rebecca A. ;
Frost, Charles E. .
CLINICAL PHARMACOKINETICS, 2019, 58 (10) :1265-1279
[27]   GOUT, URIC-ACID AND PURINE METABOLISM IN PEDIATRIC NEPHROLOGY [J].
CAMERON, JS ;
MORO, F ;
SIMMONDS, HA .
PEDIATRIC NEPHROLOGY, 1993, 7 (01) :105-118
[28]  
Casademont M, 1966, Rev Esp Reum Enferm Osteoartic, V11, P256
[29]  
Chahal Geeta, 2024, Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry, V23, P39, DOI 10.2174/0118715230275741231207115011
[30]   COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression [J].
Chandrasekharan, NV ;
Dai, H ;
Roos, KLT ;
Evanson, NK ;
Tomsik, J ;
Elton, TS ;
Simmons, DL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (21) :13926-13931